Compare Amphastar Pharmaceuticals Inc (AMPH) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Raymond James Financial, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.55 (market cap $826.08M), while Raymond James Financial, Inc. trades at $168.85 (market cap $32.76B). The key difference: Raymond James Financial, Inc. is far larger — about 39.7× Amphastar Pharmaceuticals Inc's market cap, and Raymond James Financial, Inc. pays a 1.28% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | RJF | |
|---|---|---|
Market Cap | $826.08M | $32.76B |
Sector | Health | Financials |
52-Week High | $30.81 | $176.43 |
52-Week Low | $16.87 | $140.89 |
Enterprise Value | $1.22B | — |
Dividend Yield | — | 1.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Raymond James Financial (RJF) trades at $168.12, down 0.36% today, with a bullish technical signal and strong earnings momentum after beating estimates in three consecutive quarters. Revenue growth is robust, with 2025 revenue reaching $13.84B and net income of $2.14B, though profit margins have moderated slightly. Analyst consensus is positive with a $176.83 price target, and the company maintains a solid dividend, recently declaring $0.54 per share payable in July 2026.
The outlook for RJF is favorable, supported by earnings beats and strategic investments, but risks include rising expenses and market volatility. Upside potential exists if cost management improves and revenue growth sustains, aligning with analyst targets. Key risks are competitive pressures and economic sensitivity, yet institutional sentiment remains bullish with no sell ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
